Skip to main content
SpringerLink
Log in

Effects of Derivatives of 3-Hydroxypyridine and Succinic Acid on Stereotypical Behavior and Catalepsy in Mice

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

The effects of derivatives of 3-hydroxypyridine and succinic acid (emoxypine, Reamberin, and Mexidol) on the state of cerebral dopaminergic processes were studied using catalepsy and stereotypical “verticalization” (climbing) behavior as criteria in experiments on mice. Single doses of emoxypine, Reamberin, and Mexidol at doses equivalent to the therapeutic range for humans were found to potentiate apomorphine-induced stereotypical behavior and to decrease the cataleptogenic effect of haloperidol. All studied derivatives of 3-hydroxypyridine and succinic acid increased spontaneous catalepsy. Emoxypine and Reamberin stimulated spontaneous stereotypical behavior in mice. The intrinsic cataleptogenic activity of the agents studied here correlated negatively with their influences on spontaneous stereotypical behavior. The nature of changes in stereotypical behavior and catalepsy in response to the test compounds provided evidence of an apparent similarity between their effects on dopaminergic processes and the phenotype of the pharmacological action of partial agonists of dopamine receptors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. I. A. Volchegorskii, I. I. Dolgushin, O. L. Kolesnikov, and V. E. Tseilikman, Experimental Modeling and Laboratory Evaluation of the Adaptive Reactions of the Body, Chelyabinsk State Pedagogical University Press, Chelyabinsk (2000).

    Google Scholar 

  2. I. A. Volchegorskii and N. V. Mester, “Effects of antioxidants of the 3-hydroxypyridine group on depression in patients with diabetes mellitus,” Klin. Med., No. 2, 40–45 (2007).

  3. I. A. Volchegorskii and K. M. Mester, “Effects of derivatives of 3-hydroxypyridine and succinic acid on the dynamics of pain syndrome and affective disorders after removal of herniated intervertebral disks,” Eksperim. Klin. Farmakol., 73, No. 1, 33–39 (2010).

    CAS  Google Scholar 

  4. I. A. Volchegorskii, L. M. Rassokhina, I. Yu. Miroshnichenko, K. M. Mester, P. N. Novoselov, and T. V. Astakhova, “Effects of pro- and antioxidants on insulin sensitivity and glucose tolerance,” Byull. Eksperim. Biol. Med., 150, No. 9, 295–301 (2010).

    Google Scholar 

  5. I. A. Volchegorskii, I. Yu. Miroshnichenko, L. M. Rassokhina, and R. M. Faizullin, “Studies of the antidepressant activity of derivatives of 3-hydroxypyridine and succinic acid in experiments on mice,” Eksperim. Klin. Farmakol., 76, No. 7, 6–10 (2013).

    CAS  Google Scholar 

  6. I. A. Volchegorskii, I. Yu. Miroshnichenko, L. M. Rassokhina, R. M. Faizullin, and K. E. Pryakhina, “Effects of derivatives of 3-hydroxypyridine and succinic acid on obsessive-compulsive activity in mice in the ‘ball burying’ test,” Eksperim. Klin. Farmakol., 77, No. 10, 10–14 (2014).

    CAS  Google Scholar 

  7. I. A. Volchegorskii, I. Yu. Miroshnichenko, L. M. Rassokhina, R. M. Faizullin, K. E. Pryakhina, M. P. Malkin, and A. V. Kalugina, “Experimental studies of the effects of derivatives of 3-hydroxypyridine and succinic acid on resistance to acute cerebral ischemia,” Zh. Nevrol. Psikhiat. im. S. S. Korsakova, No. 12, 123–127 (2014).

  8. T. A. Voronina, “The antioxidant Mexidol. Main neuropsychotropic effects and mechanism of action,” Psikhofarmakol. Biol. Narkol., 1, No. 1, 2–12 (2001).

    Google Scholar 

  9. V. P. Galenko-Yarosheskii, O. N. Gulevskaya, A. V. Zelenskaya, V. V. Seletskaya, S. K. Bogus, V. L. Popkov, and S. V. Gatsura, “Current challenges in the correction of impairments to oxidative homeostasis in experimental pharmacology,” Nov. Tekhnol., No. 2, 166–171 (2011).

  10. European Convention of the Protection of Vertebrates Used for Experimental or Other Scientific Purposes, EST No. 123 of March 18, 1986, Strasbourg (1986).

  11. E. A. Katunina, “The potential for the use of antioxidant therapy in patients with Parkinson’s disease,” Eksperim. Klin. Farmakol., 68, No. 5, 18–20 (2005).

    Google Scholar 

  12. E. S. Kovaleva, L. L. Prilipko, K. O. Muranov, and V. E. Kagan, “Actions of antioxidants on release of 3H-serotonin by rat brain synaptosomes,” Byull. Eksperim. Biol. Med., 96, No. 10, 55–57 (1983).

    CAS  Google Scholar 

  13. O. A. Popova, V. S. Kudrin, P. M. Klodt, V. B. Narkevich, L. N. Nerobkova, I. G. Kapitsa, T. A. Voronina, and E. A. Val’dman, “Effects of Mexidol on neurochemical changes in rat brain structures in modeling of Parkinson’s syndrome,” Vestn. Ros. Gos. Med. Univ., No. 1, 54–58 (2008).

  14. K. S. Raevskii, “Current neuroleptics: interaction with brain neurotransmitter systems,” Psikh. Psikhofarmakoter., 2, No. 5, 132–134 (2000).

    Google Scholar 

  15. Guidelines for Preclinical Studies of Medicines, A. N. Mironov (ed.) Grif i K, Moscow (2012).

  16. K. Yu. Sarkisova, M. A. Kulikov, I. S. Midzyanovskaya, and A. A. Folomkina, “The dopamine-dependent nature of depression-like behavior in WAG/Rij rats with genetic absence epilepsy,” Zh. Vyssh. Nerv. Deyat. I. P. Pavlova, 57, No. 1, 91–102 (2007).

    CAS  Google Scholar 

  17. L. Bardin, M. S. Kleven, C. Barret-Grevoz, R. Depoortere, and A. Newman-Tancredi, “Antipsychotic-like vs. cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties,” Neuropsychopharmacology, 31, 1869–1879 (2006).

    Article  CAS  Google Scholar 

  18. D. Boulay, O. Bergis, P. Avenet, and G. Griebel, “The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice,” Neuropsychopharmacology, 35, 416–427 (2010).

    Article  CAS  Google Scholar 

  19. A. Carlsson and M. L. Carlsson, “A dopaminergic deficit hypothesis of schizophrenia: the path to discovery,” Dialogues Clin. Neurosci., 8, 137–142 (2006).

    PubMed  PubMed Central  Google Scholar 

  20. R. Depoortere, L. Bardin, A. L. Auclair, M. S. Kleven, E. Prinssen, F. Colpaert, B. Packer, and A. Newman-Tancredi, “F15063, a compound with D2/D3 antagonist, 5-HT 1a agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia,” Br. J. Pharmacol., 151, 253–265 (2007).

    Article  CAS  Google Scholar 

  21. O. Erbas, H. S. Akseki, B. Elikucuk, and D. Taskiran, “Antipsychotic-like effect of trimetazidine in a rodent model,” Bull. Clin. Psychopharmacology, 24, No. 1, 40–45 (2014).

    Google Scholar 

  22. R. Frau, G. Pillolla, V. Bini, S. Tambaro, P. Devoto, and M. Bortolato, “Inhibition of 5α-reductase attenuates behavioral effects of D1-but not D2-like receptor agonists in C57BL/6 mice,” Psychoneuroendocrinology, 38, No. 4, 542–551 (2013).

    Article  CAS  Google Scholar 

  23. S. Inanir, U. S. Copoglu, H. Kokacya, R. Dokuyucu, O. Erbas, and A. Inanir, “The agomelatine protection in LPS-induced psychosis-relevant behavior model,” Med. Sci. Monit., 21, 3834–3839 (2015).

    Article  CAS  Google Scholar 

  24. F. Lavergne and T. M. Jay, “A new strategy for antidepressant prescription,” Front. Neurosci., 192. No. 4, 1–13 (2010).

    Google Scholar 

  25. D. Makmood, R. Khanam, K. K. Pillai, and M. Akktar, “Protective effects of histamine H3-receptor ligands in schizophrenic behaviors in experimental models,” Pharmacol. Rep., 64, 191–204 (2012).

    Article  Google Scholar 

  26. G. H. Perrault, R. Depoortere, E. Morel, D. J. Sanger, and B. Scatton, “Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity,” J. Pharmacol. Exp. Therap., 280, 73–82 (1997).

    CAS  Google Scholar 

  27. H. Skarifi , A. M. Nayebi, and S. Farajnia, “The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats,” Adv. Pharm. Bull., 2, No. 1, 127–131 (2012).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. South Ural State Medical University, Ministry of Health of Russia, Chelyabinsk, Russia

    I. A. Volchegorskii, I. Yu. Miroshnichenko, L. M. Rassokhina, R. M. Faizullin & K. E. Pryakhina

Authors
  1. I. A. Volchegorskii
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Yu. Miroshnichenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. M. Rassokhina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. M. Faizullin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. E. Pryakhina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. A. Volchegorskii.

Additional information

Translated from Rossiiskii Fiziologicheskii Zhurnal imeni I. M. Sechenova, Vol. 103, No. 4, pp. 406–416, April, 2017.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Volchegorskii, I.A., Miroshnichenko, I.Y., Rassokhina, L.M. et al. Effects of Derivatives of 3-Hydroxypyridine and Succinic Acid on Stereotypical Behavior and Catalepsy in Mice. Neurosci Behav Physi 48, 947–953 (2018). https://doi.org/10.1007/s11055-018-0654-9

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-018-0654-9

Keywords

Search

Navigation